gpc3 antibody  (Boster Bio)


Bioz Verified Symbol Boster Bio is a verified supplier
Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Boster Bio gpc3 antibody
    Image of <t>GPC3</t> expression of Huh-7 cells obtained by confocal laser scanning microscope. The fluorescence on the cellular membrane appears intensive.
    Gpc3 Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gpc3 antibody/product/Boster Bio
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    gpc3 antibody - by Bioz Stars, 2022-05
    92/100 stars

    Images

    1) Product Images from "Trials in developing a nanoscale material for extravascular contrast-enhanced ultrasound targeting hepatocellular carcinoma"

    Article Title: Trials in developing a nanoscale material for extravascular contrast-enhanced ultrasound targeting hepatocellular carcinoma

    Journal: PeerJ

    doi: 10.7717/peerj.10403

    Image of GPC3 expression of Huh-7 cells obtained by confocal laser scanning microscope. The fluorescence on the cellular membrane appears intensive.
    Figure Legend Snippet: Image of GPC3 expression of Huh-7 cells obtained by confocal laser scanning microscope. The fluorescence on the cellular membrane appears intensive.

    Techniques Used: Expressing, Laser-Scanning Microscopy, Fluorescence

    A was acquired at one minute, and B was acquired six hours after the initial fluorescent imaging, the fluorescent signal intensity in the tumor area has no significant difference from other areas of the body expect the liver and spleen. C was acquired 24 h after injection, the fluorescent signal could not be visualized in the mice. D, E and F were acquired from experiments of mice with Huh-7 xenograft tumors blocked using GPC3 antibody presented the same fluorescent imaging characteristics as those in the mice with Huh-7 xenograft tumors.
    Figure Legend Snippet: A was acquired at one minute, and B was acquired six hours after the initial fluorescent imaging, the fluorescent signal intensity in the tumor area has no significant difference from other areas of the body expect the liver and spleen. C was acquired 24 h after injection, the fluorescent signal could not be visualized in the mice. D, E and F were acquired from experiments of mice with Huh-7 xenograft tumors blocked using GPC3 antibody presented the same fluorescent imaging characteristics as those in the mice with Huh-7 xenograft tumors.

    Techniques Used: Imaging, Injection, Mouse Assay

    Row 1 is a study group, and rows 2–5 are control groups. (A, E, I, M and Q) Images of all xenograft tumors presented a complex of isoechogenicity, hypoechogenicity and anechogenicity obtained by convention ultrasound. (B of LSGMbs) After administration of LSPMbs suspension, tumors presented hyper-enhancement in periphery and hypo-enhancement in center (necrosis) at two seconds. (C of LSGMbs) At 60 s, the tumor still presented hyper-enhancement in periphery and hypo-enhancement in center (necrosis). (D of LSGMbs) At 10 min, the tumor presented iso-enhancement with central hypo-enhancement (necrosis). (F, G and H of LSGMbs) and (J, K and L of LSPMbs, after GPC3 blocking) and they presented similar enhancement patterns and sustain time as those in Huh-7 xenograft tumors, and there were no appreciable difference. (N, O and P of SonoVue) The xenograft tumors presented similar enhancement patterns and sustaining time as those using LSPMbs after administration of SonoVue suspension. (R, S and T of LS) The xenograft tumors did not present enhancement at 2, 20, and 60 s, and 10 min after administration of LS suspension.
    Figure Legend Snippet: Row 1 is a study group, and rows 2–5 are control groups. (A, E, I, M and Q) Images of all xenograft tumors presented a complex of isoechogenicity, hypoechogenicity and anechogenicity obtained by convention ultrasound. (B of LSGMbs) After administration of LSPMbs suspension, tumors presented hyper-enhancement in periphery and hypo-enhancement in center (necrosis) at two seconds. (C of LSGMbs) At 60 s, the tumor still presented hyper-enhancement in periphery and hypo-enhancement in center (necrosis). (D of LSGMbs) At 10 min, the tumor presented iso-enhancement with central hypo-enhancement (necrosis). (F, G and H of LSGMbs) and (J, K and L of LSPMbs, after GPC3 blocking) and they presented similar enhancement patterns and sustain time as those in Huh-7 xenograft tumors, and there were no appreciable difference. (N, O and P of SonoVue) The xenograft tumors presented similar enhancement patterns and sustaining time as those using LSPMbs after administration of SonoVue suspension. (R, S and T of LS) The xenograft tumors did not present enhancement at 2, 20, and 60 s, and 10 min after administration of LS suspension.

    Techniques Used: Blocking Assay

    2) Product Images from "Trials in developing a nanoscale material for extravascular contrast-enhanced ultrasound targeting hepatocellular carcinoma"

    Article Title: Trials in developing a nanoscale material for extravascular contrast-enhanced ultrasound targeting hepatocellular carcinoma

    Journal: PeerJ

    doi: 10.7717/peerj.10403

    Image of GPC3 expression of Huh-7 cells obtained by confocal laser scanning microscope. The fluorescence on the cellular membrane appears intensive.
    Figure Legend Snippet: Image of GPC3 expression of Huh-7 cells obtained by confocal laser scanning microscope. The fluorescence on the cellular membrane appears intensive.

    Techniques Used: Expressing, Laser-Scanning Microscopy, Fluorescence

    A was acquired at one minute, and B was acquired six hours after the initial fluorescent imaging, the fluorescent signal intensity in the tumor area has no significant difference from other areas of the body expect the liver and spleen. C was acquired 24 h after injection, the fluorescent signal could not be visualized in the mice. D, E and F were acquired from experiments of mice with Huh-7 xenograft tumors blocked using GPC3 antibody presented the same fluorescent imaging characteristics as those in the mice with Huh-7 xenograft tumors.
    Figure Legend Snippet: A was acquired at one minute, and B was acquired six hours after the initial fluorescent imaging, the fluorescent signal intensity in the tumor area has no significant difference from other areas of the body expect the liver and spleen. C was acquired 24 h after injection, the fluorescent signal could not be visualized in the mice. D, E and F were acquired from experiments of mice with Huh-7 xenograft tumors blocked using GPC3 antibody presented the same fluorescent imaging characteristics as those in the mice with Huh-7 xenograft tumors.

    Techniques Used: Imaging, Injection, Mouse Assay

    Row 1 is a study group, and rows 2–5 are control groups. (A, E, I, M and Q) Images of all xenograft tumors presented a complex of isoechogenicity, hypoechogenicity and anechogenicity obtained by convention ultrasound. (B of LSGMbs) After administration of LSPMbs suspension, tumors presented hyper-enhancement in periphery and hypo-enhancement in center (necrosis) at two seconds. (C of LSGMbs) At 60 s, the tumor still presented hyper-enhancement in periphery and hypo-enhancement in center (necrosis). (D of LSGMbs) At 10 min, the tumor presented iso-enhancement with central hypo-enhancement (necrosis). (F, G and H of LSGMbs) and (J, K and L of LSPMbs, after GPC3 blocking) and they presented similar enhancement patterns and sustain time as those in Huh-7 xenograft tumors, and there were no appreciable difference. (N, O and P of SonoVue) The xenograft tumors presented similar enhancement patterns and sustaining time as those using LSPMbs after administration of SonoVue suspension. (R, S and T of LS) The xenograft tumors did not present enhancement at 2, 20, and 60 s, and 10 min after administration of LS suspension.
    Figure Legend Snippet: Row 1 is a study group, and rows 2–5 are control groups. (A, E, I, M and Q) Images of all xenograft tumors presented a complex of isoechogenicity, hypoechogenicity and anechogenicity obtained by convention ultrasound. (B of LSGMbs) After administration of LSPMbs suspension, tumors presented hyper-enhancement in periphery and hypo-enhancement in center (necrosis) at two seconds. (C of LSGMbs) At 60 s, the tumor still presented hyper-enhancement in periphery and hypo-enhancement in center (necrosis). (D of LSGMbs) At 10 min, the tumor presented iso-enhancement with central hypo-enhancement (necrosis). (F, G and H of LSGMbs) and (J, K and L of LSPMbs, after GPC3 blocking) and they presented similar enhancement patterns and sustain time as those in Huh-7 xenograft tumors, and there were no appreciable difference. (N, O and P of SonoVue) The xenograft tumors presented similar enhancement patterns and sustaining time as those using LSPMbs after administration of SonoVue suspension. (R, S and T of LS) The xenograft tumors did not present enhancement at 2, 20, and 60 s, and 10 min after administration of LS suspension.

    Techniques Used: Blocking Assay

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Boster Bio gpc3 antibody
    Image of <t>GPC3</t> expression of Huh-7 cells obtained by confocal laser scanning microscope. The fluorescence on the cellular membrane appears intensive.
    Gpc3 Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gpc3 antibody/product/Boster Bio
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    gpc3 antibody - by Bioz Stars, 2022-05
    92/100 stars
      Buy from Supplier

    Image Search Results


    Image of GPC3 expression of Huh-7 cells obtained by confocal laser scanning microscope. The fluorescence on the cellular membrane appears intensive.

    Journal: PeerJ

    Article Title: Trials in developing a nanoscale material for extravascular contrast-enhanced ultrasound targeting hepatocellular carcinoma

    doi: 10.7717/peerj.10403

    Figure Lengend Snippet: Image of GPC3 expression of Huh-7 cells obtained by confocal laser scanning microscope. The fluorescence on the cellular membrane appears intensive.

    Article Snippet: Experiment carried out in the mice blocked previously by injection of GPC3 antibody or synthesized peptide presented the same fluorescent imaging characteristics as those in the mice with Huh-7 xenograft tumors ( – ).

    Techniques: Expressing, Laser-Scanning Microscopy, Fluorescence

    A was acquired at one minute, and B was acquired six hours after the initial fluorescent imaging, the fluorescent signal intensity in the tumor area has no significant difference from other areas of the body expect the liver and spleen. C was acquired 24 h after injection, the fluorescent signal could not be visualized in the mice. D, E and F were acquired from experiments of mice with Huh-7 xenograft tumors blocked using GPC3 antibody presented the same fluorescent imaging characteristics as those in the mice with Huh-7 xenograft tumors.

    Journal: PeerJ

    Article Title: Trials in developing a nanoscale material for extravascular contrast-enhanced ultrasound targeting hepatocellular carcinoma

    doi: 10.7717/peerj.10403

    Figure Lengend Snippet: A was acquired at one minute, and B was acquired six hours after the initial fluorescent imaging, the fluorescent signal intensity in the tumor area has no significant difference from other areas of the body expect the liver and spleen. C was acquired 24 h after injection, the fluorescent signal could not be visualized in the mice. D, E and F were acquired from experiments of mice with Huh-7 xenograft tumors blocked using GPC3 antibody presented the same fluorescent imaging characteristics as those in the mice with Huh-7 xenograft tumors.

    Article Snippet: Experiment carried out in the mice blocked previously by injection of GPC3 antibody or synthesized peptide presented the same fluorescent imaging characteristics as those in the mice with Huh-7 xenograft tumors ( – ).

    Techniques: Imaging, Injection, Mouse Assay

    Row 1 is a study group, and rows 2–5 are control groups. (A, E, I, M and Q) Images of all xenograft tumors presented a complex of isoechogenicity, hypoechogenicity and anechogenicity obtained by convention ultrasound. (B of LSGMbs) After administration of LSPMbs suspension, tumors presented hyper-enhancement in periphery and hypo-enhancement in center (necrosis) at two seconds. (C of LSGMbs) At 60 s, the tumor still presented hyper-enhancement in periphery and hypo-enhancement in center (necrosis). (D of LSGMbs) At 10 min, the tumor presented iso-enhancement with central hypo-enhancement (necrosis). (F, G and H of LSGMbs) and (J, K and L of LSPMbs, after GPC3 blocking) and they presented similar enhancement patterns and sustain time as those in Huh-7 xenograft tumors, and there were no appreciable difference. (N, O and P of SonoVue) The xenograft tumors presented similar enhancement patterns and sustaining time as those using LSPMbs after administration of SonoVue suspension. (R, S and T of LS) The xenograft tumors did not present enhancement at 2, 20, and 60 s, and 10 min after administration of LS suspension.

    Journal: PeerJ

    Article Title: Trials in developing a nanoscale material for extravascular contrast-enhanced ultrasound targeting hepatocellular carcinoma

    doi: 10.7717/peerj.10403

    Figure Lengend Snippet: Row 1 is a study group, and rows 2–5 are control groups. (A, E, I, M and Q) Images of all xenograft tumors presented a complex of isoechogenicity, hypoechogenicity and anechogenicity obtained by convention ultrasound. (B of LSGMbs) After administration of LSPMbs suspension, tumors presented hyper-enhancement in periphery and hypo-enhancement in center (necrosis) at two seconds. (C of LSGMbs) At 60 s, the tumor still presented hyper-enhancement in periphery and hypo-enhancement in center (necrosis). (D of LSGMbs) At 10 min, the tumor presented iso-enhancement with central hypo-enhancement (necrosis). (F, G and H of LSGMbs) and (J, K and L of LSPMbs, after GPC3 blocking) and they presented similar enhancement patterns and sustain time as those in Huh-7 xenograft tumors, and there were no appreciable difference. (N, O and P of SonoVue) The xenograft tumors presented similar enhancement patterns and sustaining time as those using LSPMbs after administration of SonoVue suspension. (R, S and T of LS) The xenograft tumors did not present enhancement at 2, 20, and 60 s, and 10 min after administration of LS suspension.

    Article Snippet: Experiment carried out in the mice blocked previously by injection of GPC3 antibody or synthesized peptide presented the same fluorescent imaging characteristics as those in the mice with Huh-7 xenograft tumors ( – ).

    Techniques: Blocking Assay